Second-Line Isn't Second Best

2 Recommendations

A drug company's decision to get approved as a first-line treatment for a disease (versus a second-line one) is usually tricky. The first-line market is obviously larger, but usually has more competition. Adding further complexity to the decision, patients who've failed first-line treatments are usually harder to treat.

On the other hand, Schering-Plough's (NYSE: SGP) move in the European hepatitis C market was really quite easy. It's PEGINTRON and REBETOL combination therapy is already approved as a front-line treatment, and there aren't any drugs approved in Europe to treat cases that have failed other therapies. A market with no competition -- at least on the marketing level -- should work wonders for sales.

The company moved one step closer to its goal on Monday, when the Committee for Medicinal Products for Human Use (CHMP) recommended approval of the combination therapy PEGINTRON and REBETOL for retreating patients. The European Medicines Agency (EMEA) will get the final say on whether the drug is approved for marketing.

PEGINTRON is approved for treating hepatitis C in the U.S., both by itself and in combination with REBETOL as a front-line treatment. Its main competition both in the U.S. and Europe comes from Roche's Pegasys. The second-line treatment approval should set Schering apart -- at least in Europe. There's no word on whether the company will try to get a second-line designation in the U.S.

Schering-Plough needs all the additional sales from second-line treatments it can get. Up-and-coming stars including Vertex Pharmaceuticals' (Nasdaq: VRTX) telaprevir, with its stellar phase 2 data, and Pharmasset's (Nasdaq: VRUS) R7128 -- which will be tested in combination with Roche's Pegasys -- might be able to take front-line treatment market share if they're approved.

What do the unfolding financial crisis and ongoing market volatility mean for your money? The Fool's here with answers. Get the best of our daily commentary and analysis in your inbox simply by entering your email address in the box below.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 537507, ~/articles/articlehandler.aspx, 11/21/2008 9:24:44 PM,

Sign up for FREE Motley Fool site access!

Already registered? Login Here

It’s FREE! Enter your email address, and we’ll rush you to the article you're looking for right now.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Related Tickers

Schering-Plough Corp

SGP Up! $14.34 +0.90 (+6.70%) 4:00 PM
CAPS Rating:
1027 Outperforms
58 Underperforms
Rate This Stock

Major Indices

S&P 500800.03+6.32%
DJIA8,046.42+6.54%
NASD1,384.35+5.18%
Updated: 4:07:36 PM
Sponsored by:

The Motley Poll

What changes are you making to your portfolio?

Sponsored by: